Zeidan, Amer M.
Bewersdorf, Jan Philipp http://orcid.org/0000-0003-3352-0902
Hasle, Vanessa
Shallis, Rory M. http://orcid.org/0000-0002-8542-2944
Thompson, Ethan
de Menezes, Daniel Lopes http://orcid.org/0000-0001-7953-7625
Rose, Shelonidta
Boss, Isaac
Halene, Stephanie http://orcid.org/0000-0002-2737-9810
Haferlach, Torsten
Fox, Brian
Article History
Received: 15 September 2022
Revised: 10 November 2022
Accepted: 14 November 2022
First Online: 27 November 2022
Competing interests
: AMZ received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. AMZ participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, and Tyme. AMZ served on clinical trial committees for Novartis, Abbvie, Gilead, BioCryst, Abbvie, ALX Oncology, Geron and Celgene/BMS. RMS participated in advisory boards, and/or had a consultancy with and received honoraria from Bristol Myers Squibb and Gilead Sciences, Inc; divested equity interest in Curis Oncology. IB, ET, BAF, VEH, and SR are employees of Celgene, a Bristol Myers Squibb company, and may be shareholders. SH has received research funding received honoraria from FORMA Therapeutics. TH is the owner of Munich Leukemia Laboratory. All other authors have no relevant conflicts of interest to declare.